Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers by Zhou, Jian-Ping et al.
Systems Biology Modeling Reveals a Possible Mechanism
of the Tumor Cell Death upon Oncogene Inactivation in
EGFR Addicted Cancers
Jian-Ping Zhou
1,2., Xin Chen
1., Shan Feng
1., Shi-Dong Luo
1., You-Li Pan
1, Lei Zhong
1, Pan Ji
1, Ze-Rong
Wang
1, Shuang Ma
1, Lin-Li Li
1, Yu-Quan Wei
1, Sheng-Yong Yang
1*
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China, 2Medical School,
Panzhihua University, Panzhihua, Sichuan, People’s Republic of China
Abstract
Despite many evidences supporting the concept of ‘‘oncogene addiction’’ and many hypotheses rationalizing it, there is still
a lack of detailed understanding to the precise molecular mechanism underlying oncogene addiction. In this account, we
developed a mathematic model of epidermal growth factor receptor (EGFR) associated signaling network, which involves
EGFR-driving proliferation/pro-survival signaling pathways Ras/extracellular-signal-regulated kinase (ERK) and phosphoino-
sitol-3 kinase (PI3K)/AKT, and pro-apoptotic signaling pathway apoptosis signal-regulating kinase 1 (ASK1)/p38. In the
setting of sustained EGFR activation, the simulation results show a persistent high level of proliferation/pro-survival
effectors phospho-ERK and phospho-AKT, and a basal level of pro-apoptotic effector phospho-p38. The potential of p38
activation (apoptotic potential) due to the elevated level of reactive oxygen species (ROS) is largely suppressed by the
negative crosstalk between PI3K/AKT and ASK1/p38 pathways. Upon acute EGFR inactivation, the survival signals decay
rapidly, followed by a fast increase of the apoptotic signal due to the release of apoptotic potential. Overall, our systems
biology modeling together with experimental validations reveals that inhibition of survival signals and concomitant release
of apoptotic potential jointly contribute to the tumor cell death following the inhibition of addicted oncogene in EGFR
addicted cancers.
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Introduction
The concept of ‘‘oncogene addiction’’ was firstly raised by
Weinstein based on the peculiar phenomena that the proliferation
and survival of some cancers strongly depend on only one
oncogenic protein or pathway, despite the presence of multiple
gene mutations and epigenetic abnormalities [1–3]. Now a lot of
evidences have been found to support this concept, including those
from genetically engineered mouse models [4,5], mechanistic
studies in human cancer cell lines [6,7], and particularly the good
clinical therapeutic efficacy of a series of antibodies or small
molecular drugs that target specific proteins in human cancers
reported in recent years [8–10]. Currently several hypotheses have
been proposed to explain the phenomenon of oncogene addiction,
including genetic streamlining [11,12], synthetic lethality [13],
oncogenic amnesia [14], and oncogenic shock [15,16]. These
hypotheses give various explanations from different angles to the
phenomenon of oncogene addiction. Even so, there is still a lack of
detailed understanding to the precise mechanism underlying the
oncogene addiction. In particular, the molecular basis of some
essential phenomena related to the oncogene addiction remains
unclear, for example, the phenomenon that acute oncogene
inactivation leads to tumor cell death in the oncogene addicted
cancers, while sparing other cells that are not similarly addicted.
It has been suggested that the abnormity of intracellular
circuitry (signal transduction network) or ‘‘wiring diagram’’ is the
most fundamental reason that accounts for the phenomena of
oncogene addiction [2,17]. The complexity of intracellular
circuitry together with multi-genetic mutations in cancer cells
hampers the understanding of molecular basis underpinning
oncogene addiction [18,19]. The situation has now changed a
little due to recent advances in systems biology [20–22],
particularly the computational systems biology [23,24]. Thus,
one is currently in a good position to apply such technologies to
reveal possible molecular mechanisms underlying various phe-
nomena associated with the oncogene addiction.
As the first work of understanding the oncogene addiction from the
viewpointofsystemsbiology,inthisstudy,wedevelopedamathematic
model of epidermal growth factor receptor (EGFR)-associated
signaling network to investigate possible molecular mechanism of
the tumor cell death following the inhibition of addicted oncogene.
Here we chose the EGFR-associated signaling network mainly due to
the following reasons: (1) EGFR is one of the most important
oncogenes and implicated in many human tumor types, in particular,
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networkhasbeenwidelystudiedexperimentallyandtheoretically[27–
30], implying that many parameters are available in literature that
facilitates the model development. This model was validated first, and
then utilized to simulate the normal state of cancer cells and network
responses upon acute EGFR inhibition.
Results
Establishment of the mathematic model of EGFR-
associated signaling network
We here present an ordinary differential equation (ODE) based
mathematic model of EGFR-associated signaling network, which
involves EGFR-driving proliferation/pro-survival signaling path-
ways Ras/extracellular-signal-regulated kinase (ERK) and phos-
phoinositol-3 kinase (PI3K)/AKT, and pro-apoptotic signaling
pathway apoptosis signal-regulating kinase 1 (ASK1)/p38. The
portions of Ras/ERK and PI3K/AKT pathways in this model
were established based on the known Ras/ERK and PI3K/AKT
models including such as Brightman [31], Birtwistle [30],
Schoeberl [29], and Oda [32] models. To the authors’ knowledge,
however, there is no mathematic model of p38 mediated pro-
apoptotic signaling pathway reported yet in literature. We thus
built a model of p38 signaling and incorporated it into the EGFR
signaling network. The model comprises 243 equations and
interactions with 160 distinct molecular species, characterized by
145 kinetic parameters and 28 non-zero initial molecular
concentrations. Most of the kinetic parameters and initial
molecular concentrations in this model were taken from literature
or derived from basic physicochemical quantities [29,30,33].
Others were estimated by fitting model outputs to known
experimental data with the use of hybrid quasi ensemble modeling
algorithm proposed by us recently [34]. The main reactions and
parameters are presented in Table S1, and initial molecular
concentrations in Table S2 (see Supporting Information). The
important signaling pathways and key components involved in our
network model are shown in Figure 1. A brief description for this
EGFR-associated network is given as follows.
Figure 1. Simplified schematic representation of the EGFR-associated signaling network model established in this study. Solid lines
with arrows indicate the activation of proteins or lipids. Dotted lines represent direct protein–protein and protein–lipid interactions. Solid lines with
blunt ends represent inhibition.
doi:10.1371/journal.pone.0028930.g001
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binding of epidermal growth factor (EGF) to EGFR, followed by
the dimerization and subsequent mutual trans-phosphorylation on
several tyrosine residues of EGFR; although EGFR family has
other three members including ErbB2, ErbB3, and ErbB4 in
addition to EGFR (ErbB1) which can form different dimmers
(either homo- or hetero-dimers) [30,35], just EGFR and EGFR-
EGFR homo-dimers are considered in this model for simplifica-
tion. These phospho-tyrosine residues act as docking sites that
enable receptors to recruit adaptor proteins Shc and Grb2 [36],
which can then recruit the guanosine nucleotide exchange factor
SOS. SOS promotes the replacement of GDP by GTP in Ras,
thereby activating Ras [37]. The activated Ras subsequently
results in the activation of protein kinase Raf [38]; since the direct
activator of Raf kinase is not known yet, we assume that Raf
phosphorylation is caused directly by a Ras-GTP molecule in this
model. The activated Raf finally activates the mitogen-activated
protein kinase kinase1/2 (MEK) and ERK in a cascade way [39].
The activated ERK can phosphorylate the upstream protein SOS,
hence causing the dissociation of Grb2-SOS from the receptor
complex, which forms a negative feedback loop [40]. In addition,
Grb2 in cytomembrane can also recruit Gab1, which causes the
phosphorylation of Gab1 and the consequent recruitment of PI3K
[41]. In cytomembrane, PI3K transforms phosphatidylinositol 4,5-
bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate
(PIP3) that induces the activation of AKT through cooperating
with 3-phosphoinositide dependent protein kinase-1 (PDK1) [42].
In this process, phosphatase and tensin homolog (PTEN) and
protein phosphatase 2A (PP2A) can specifically dephosphorylate
PIP3 and AKT respectively [43]. Phosphorylated Raf, MEK and
ERK can be dephosphorylated by their specific phosphatases [30].
P38 that is thought as an important pro-apoptotic effector can
be activated by a variety of environmental stresses and
inflammatory cytokines [44–46]. Among which, of particular
importance is the stress due to reactive oxygen species (ROS). For
example, Dolado et al. reported that the oncogenic H-Ras-
induced ROS plays a key role in the inhibition of tumor initiation
by activating p38 and hence resulting in apoptosis in fibroblasts
derived from mouse embryos [47]. Moreover numerous studies
have demonstrated that stimulation of human cancer cells with
EGF results in an increase in the intracellular concentration of
ROS [48–50]. Jin and his colleagues even detected the rate of
ROS generation induced by EGF stimulation in A431 [50]. Thus,
ROS is involved in our model as an important upstream
component of p38 signaling pathway. ROS triggers the activation
of ASK1, which then induces the phosphorylation of mitogen-
activated protein kinase kinase3/6 (MKK) and p38 in a cascade
style [51]. Specific phosphatases of ASK1, MKK and p38 are also
included in this model. In addition, it has been established that
activated AKT can suppress the activation of p38 via phosphor-
ylating ASK1, which forms a negative crosstalk between PI3K/
AKT and ASK1/p38 signaling pathways. For instance, Zhang et
al. reported that AKT can phosphorylate ASK1 at site Ser83 to
inhibit hydrogen peroxide-induced ASK1/p38 signaling activation
in endothelial cells [52]. Yuan and his collegues also proved that
AKT can inhibit the cisplatin-induced p38 activation through
phosphorylation of ASK1 [53]. Accordingly, the crosstalk AKT-
ASK1 between PI3K/AKT and ASK1/p38 signaling pathways is
also involved in our model.
Model validation
The established model was validated by calculating the time
courses of several key species activation including Ras, ERK,
AKT and p38 after a short EGF stimulation and comparing the
simulation results with other published experimental or simula-
tion studies on EGFR signaling. Figure 2 shows the simulated
time course patterns of Ras, ERK, AKT and p38 activation
exposure to EGF with varying concentrations over 60 minutes.
Upon addition of EGF at t=0, the total concentrations of Ras-
GTP, phospho-ERK (p-ERK) and phospho-AKT (p-AKT)
rapidly increase to a maximum within 5 minutes with their
peaks depending on the EGF concentration, followed by decaying
to their basal levels within 50 minutes. Meantime, a delayed
increase of phospho-p38 (p-p38), which is peaked after 15 min-
utes, is observed. These are consistent with previous experimental
findings. For instance, EGF stimulation of PC12 cells results in a
rapid, transient activation of Ras and ERK [27]. The level of
Ras-GTP rapidly reaches a maximum within 2 minutes exposure
to EGF, but declines within 10 minutes and gradually returns to
the basal level within 60 minutes. Similarly, ERK activation is
maximal within 5 minutes, and decays to less than 50% of the
maximum level by 30 minutes, and to less than 25% within
60 minutes. The transient activations of ERK and p38 after EGF
stimulation was also observed in retinal capillary endothelial cells
[54]. After a 5-minute exposure of retinal capillary endothelial
cells to EGF, ERK reaches a maximum level of phosphorylation
that is 20-fold greater than that of its control. During the
subsequent 2 hours, ERK activation decays until it reaches a
baseline. For p-p38, it increases a level nearly threefold relative to
its control after 15 minutes, followed by a decline to its control
level.
Simulation of sustained activation of EGFR
We then simulate the sustained EGFR activation in EGFR
addicted cancer cells. For this purpose, the receptor internalization
reactions were removed from the model, and the EGF
concentration was set to a fixed value. Figure 3 presents the time
courses of ERK, AKT and p38 activation. Clearly, the sustained
EGFR activation finally results in a stable high level of p-ERK and
p-AKT after a rapid increase in the beginning. However, p38
activation still keeps at its basal level although a detectable small
peak of p-p38 within the first 5 minutes. Overall, the sustained
activation of EGFR leads to a final result of persistent high level of
p-ERK and p-AKT, but a low level of p-p38. This is consistent
with experimental findings in EGFR addicted cancer cells that the
ERK and AKT keep in a high level of activation and the p38
maintains in a low level of activation [16].
Simulation of the network response upon acute EGFR
inactivation in EGFR addicted cancer cells
We have just simulated the normal state of EGFR addicted
cancer cells, namely a setting of sustained EGFR activation. In this
section, we shall simulate the network response upon acute EGFR
inactivation, which mimics the situation of using the EGFR
inhibitors in EGFR addicted cancer cells. In this simulation, the
acute EGFR inactivation was carried out through a pre-assigned
event at a fixed time point, namely the EGFR activity was set to its
basal level. Changes in concentration of activated ERK, AKT and
p38 after acute EGFR inhibition are shown in Figure 4.
Obviously, the acute EGFR inactivation leads to an immediate
decline of the concentration of p-ERK and p-AKT, and a delayed
increase of p-p38. The simulation well reproduced the experi-
mental phenomena that acute inactivation of EGFR oncogene
results in a rapid diminution of the cell proliferation/pro-survival
effectors p-ERK and p-AKT, and subsequent engagement of the
pro-apoptotic effector p-p38 in EGFR addicted cancer cells
[16,55].
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the p38 activation
Sensitivity analysis has long been used in systems biology to
study how variation of the value of the simulated output of a
mathematical model can be apportioned to different sources of
variation in the input of a model, which can be used to identify
critical proteins that dominate the output of an effector protein
[29]. Here p-ERK, p-AKT and p-p38 were taken as the output
variables for the sensitivity analysis. Figure 5 presents the
normalized time-integrated sensitivity for species with nonzero
values in the EGFR signaling network model. Obviously, the most
sensitive nodes for ERK activation are MEK and Raf in addition
to the incurious ERK and EGF; ERK and EGF are the trivial
solutions since ERK is the direct precursor of p-ERK, and EGF is
the initiator of the network response (for simplicity, these incurious
sensitive nodes will be ignored later). For AKT activation, the most
sensitive nodes include Grb2, PIP2, Gab1, PI3K, PDK1, SOS,
and PTEN. And those for the activation of p38 mainly include
ASK1, MKK, RacGDP, PP2A, AKT, PDK1 and SOS.
The sensitivity analysis above reveals the critical regulators in
the network for the survival effectors p-ERK and p-AKT, and pro-
apoptotic effector p-p38. We also observed that the largest positive
and negative values of sensitivity all correspond to the output
variable p-p38. For example, AKT that has the largest negative
value of sensitivity to the pro-apoptotic effector p-p38 may play an
important negative regulation role in cell apoptosis. ASK1, MKK
and RacGDP, which all are the key components of ROS/ASK1/
MKK/p38 signaling cascade, have the largest positive values of
sensitivity, implying a key positive role of ROS associated signaling
in cell apoptosis. These findings may also be related to the
Figure 3. Simulation of the protein phosphorylation profiles at sustained activation of EGFR. Concentration changes of (A) active ERK
(phospho-ERK), (B) active AKT (phospho-AKT) and (C) active p38 (phospho-p38) upon sustained stimulation of EGFR at different levels.
doi:10.1371/journal.pone.0028930.g003
Figure 2. Simulation of the phosphorylation profiles of some critical signals under transient EGF stimulation. Concentration changes
of (A) active ERK (phospho-ERK), (B) active AKT (phospho-AKT), (C) active Ras (Ras-GTP) and (D) active p38 (phospho-p38) upon transient stimulation
by EGF at different concentrations.
doi:10.1371/journal.pone.0028930.g002
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order to test this hypothesis, we changed the original network by
removing either the crosstalk AKT-ASK1 or ROS, and then re-
simulated the network responses in the settings of sustained EGFR
activation and acute EGFR inactivation. Figure 6A presents the
simulation results when removing the crosstalk AKT-ASK1.
Obviously, high levels of p-ERK and p-AKT in the setting of
sustained EGFR activation and a rapid drop upon acute EGFR
inhibition (see Figure 6A) were observed, which are very similar to
the modeling results obtained on the original network. However,
after removing the crosstalk AKT-ASK1, p-p38 keeps in a high
level in the case of either sustained EGFR activation or acute
EGFR inhibition, implying a stronger apoptotic capacity.
Figure 6B depicts the modeling results when removing ROS.
Similar to the case when removing AKT-ASK1, we still monitored
high levels of p-ERK and p-AKT in the setting of sustained EGFR
activation and a rapid drop upon acute EGFR inhibition.
However, ROS removal resulted in a low level of p-p38 in the
case of either sustained EGFR activation or acute EGFR
inactivation. These data show that removal of ROS leads to the
loss of apoptotic capacity.
Collectively, the simulation results obtained here suggest that
there is a stronger apoptotic potential existing in the normal state
of cancer cells, which is suppressed by the negative crosstalk AKT-
ASK1 between PI3K/AKT and ASK1/p38 signaling pathways.
The release of the apoptotic potential due to the fading away of
negative crosstalk AKT-ASK1 upon EGFR inactivation could be
an important factor causing the cell death, in addition to the
Figure 4. Simulation of the molecular responses upon acute EGFR inhibition. Profile of concentration changes of (A) active ERK (phospho-
ERK), (B) active AKT (phospho-AKT) and (C) active p38 (phospho-p38). The virtual event of EGFR inhibition was performed at time 0 hr.
doi:10.1371/journal.pone.0028930.g004
Figure 5. Sensitivity analysis of model species. Normalized time-integrated sensitivities of ERK, AKT and p38 phosphorylation (p-ERK, p-AKT,
and p-p38) to each nonzero species in the EGFR-associated network model.
doi:10.1371/journal.pone.0028930.g005
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rapid release of accumulated apoptotic potential could be a key
reason that leads to the sensitivity of tumor cells to the killing
effects of drugs that target the addicted oncogene.
Experimental evidences for the existence of ROS and
apoptotic potential in EGFR-addicted cancer cells
The model described above is somewhat artificial, which may
not correspond closely with the actual EGFR addicted cancer
cells. Therefore, we also performed a series of experiments to
examine several key issues related to our modeling. Two non-small
cell lung cancer (NSCLC) cell lines HCC827 and NCI-H460
(H460) were selected for the experiments; HCC827 is a typical
EGFR addicted cancer cell line, and H460 is not EGFR addicted,
which is for comparison. The first experiment was devised to
investigate ROS levels in the two NSCLC cell lines. The
intracellular ROS level was displayed by 29,79-dichlorodihydro-
fluorescein diacetate (DCFH-DA) [56], a ROS responsive
molecular probe, and visualized by using an inverted fluorescence
microscope. As shown in Figure 7, a very high level of ROS was
detected in the EGFR-addicted HCC827 cells, whereas ROS
could hardly be perceived in H460 cells. This finding reflects one
fact that HCC827 suffers a large ROS stress, or in other words,
HCC827 bears a stronger apoptotic potential. Even so HCC827
still keeps vigorous proliferation ability, suggesting that the
apoptotic potential is well suppressed.
Subsequently western blot analysis and flow cytometry (FCM)
assays were used to investigate whether the activation of p38 as
well as the apoptosis of cancer cells can be triggered through AKT
inhibition. We treated HCC827 and H460 cells with 1 mM
wortmannin; wortmannin is an inhibitor of PI3K/AKT signaling.
As shown in Figure 8A, wortmannin treatment of HCC827 cells
can cause almost complete inhibition of AKT and large
accumulation of p-p38 within 4 hours of treatment. For H460
cells, wortmannin treatment can also cause almost complete
inhibition of the AKT, but very small accumulation of p-p38
without changing the intracellular ROS level (Figure S1). The
results of FCM assays (Figure 8B) show that wortmannin treatment
can result in increases of apoptosis rates both in HCC827 and
H460 cells. In comparison with H460, HCC827 cells exhibited
much more apoptosis after 10 mM wortmannin treatment. These
experiments demonstrate that the inactivation of survival effector
p-AKT leads to the rapid release of accumulated apoptotic
potential in EGFR-addicted cancer cells, which may be an
important reason that leads to the sensitivity of tumor cells to drugs
that target the addicted oncogene EGFR.
Since we have demonstrated the existence of apoptotic potential
due to ROS stress in EGFR-addicted cancer cells, we further
postulate that the easement of ROS stress may desensitize the
cancer cells to the targeted treatment. To test this hypothesis, we
treated HCC827 cells with vitamin c, an antioxidant that can be
used to partly mitigate the ROS stress. Then FCM and western
blot assays were carried out to test the cell apoptosis exposure to
the EGFR inhibitor gefitinib. As shown in Figure 9A, vitamin c
can decrease the apoptosis of HCC827 cells treated by gefitinib
compared with the control in which no vitamin c was used.
Figure 9B depicts the results of western blot assays, which show
that the mitigation of ROS indeed reduced the p-p38 level in
HCC827 cells treated by gefitinib. At the same time, we also
noticed that the alleviation of ROS decreased the p-ERK and p-
Figure 6. Influences of removing either the crosstalk AKT-ASK1 or ROS on the p-ERK, p-AKT and p-p38 levels. The virtual event of
EGFR inhibition was performed at time 0 hr. (A) The effects of removing crosstalk AKT-ASK1 on the concentration changes of p-ERK, p-AKT and p-P38.
(B) The effects of ROS removal on the concentration changes of p-ERK, p-AKT and p-P38.
doi:10.1371/journal.pone.0028930.g006
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stress can promote proliferation/survival, in addition to induce
apoptosis [57–59], hence the mitigation of ROS consequentially
leads to a decrease of p-ERK and p-AKT. We acknowledge that
this did not get reflection from our modeling results since our
mathematic model ignored the signaling from ROS to ERK/
AKT, which is not known at present. In addition, a MTT assay
was carried out to test the viability of HCC827 cells. The result
shows that vitamin c can decrease the cytotoxicity of gefitinib in
HCC827 cells (Figure 9C). These results suggest that the sensitivity
of HCC827 cells to the EGFR inhibitor gefitinib is reduced due to
the mitigation of apoptotic potential.
Discussion
The concept of ‘‘oncogene addiction’’ has now been accepted
by more and more researchers through the past decade.
Nevertheless, the mechanism underlying the oncogene addiction
is far from understood. In this investigation, we developed a
mathematic model of EGFR-associated signaling network. We
acknowledge that the established network model does not include
all the signaling pathways and components that regulate the
survival and apoptosis of cancer cells; establishment of a complete
network model is impractical at present. From another point of
view, ignoring other alternative signaling pathways may give a
lucky fluke that the established model more closes to the EGFR
addicted state.
Simulations with the validated EGFR-associated network model
together with the experimental validation reveal the existence of
apoptotic potential. The apoptotic potential could be induced by
various stresses, typically for example, ROS. Cancer cells often
show increased levels of intracellular ROS [60,61]. Many factors
may contribute to ROS generation [61]. The activation of
oncogene EGFR can bring on ROS generation via the sequential
activation of PI3K, Rac and NADPH oxidase [48]. In addition,
hypoxia-reperfusion in the tumor microenvironment can lead to
ROS production, which in turn can initiate a viscous cycle of
mitochondrial damage and further ROS generation [62]. In
normal cells, the ROS could be alleviated by engaging glycolysis
and down-regulating mitochondrial function [63]. Cancer cells
often have deficiency in the ROS reduction system due to genetic
alterations, which hinder the clearance of ROS [61]. The
accumulation of ROS usually results in the apoptosis through
the sequential ROS/ASK1/p38 activation [47,64]. Nevertheless,
the activation of pro-apoptotic effector p38 is inhibited by negative
crosstalk AKT-ASK1 in cancer cells [52,65]. Once the mitigation
of negative crosstalk AKT-ASK1, through for example, inactiva-
tion of AKT, the apoptotic potential can be released, hence
inducing cell apoptosis [53].
The rapid release of accumulated apoptotic potential following
oncogene inhibition is an important reason that leads to the
sensitivity of tumor cells to the killing effects of drug that target the
addicted oncogene, which is the most important hallmark of
oncogene addiction. However, it does not mean that the overall
apoptotic outcome in response to oncogene inactivation is
contributed only by the apoptotic potential. It has been recognized
that EGFR can produce pro-apoptotic outcome through activat-
ing some downstream effector pathways that have been linked to
Figure 7. ROS levels in HCC827 and H460 cells. The ROS probe signals as well as the DAPI nuclear localization in HCC827 and H460 were
presented alone or merged (Merge).
doi:10.1371/journal.pone.0028930.g007
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the so-called ‘‘death ligand’’ FAS/CD95 [66], hence leading to
apoptotic outcome. The downstream Ras can be pro-apoptotic via
an interaction with the effector target Nore1 [67].
Findings in this study may also have clinical implications in
targeted cancer therapies as well as in the anti-cancer drug
development. For example, sole use of ERK or AKT inhibitor
may not bring a good therapeutic effect even to patients with
Figure 8. AKT inhibition induces differential p38 phosphorylation and apoptosis in HCC827 and H460. (A) Immunoblotting with
indicated antibodies to show the phosphorylation of AKT and p38 in HCC827 and H460 cells treated with 1 mM wortmannin (WM). (B) Apoptosis of
HCC827 and H460 cells with or without 10 mM wortmannin (WM) treatment for 24 hours. The apoptosis rates are given as percentages.
doi:10.1371/journal.pone.0028930.g008
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PI3K/AKT inhibition did not promote substantial apoptosis in
the EGFR addicted cancers. However, blockading both PI3K/
AKT and Ras/MEK simultaneously led to apoptosis to similar
levels as the EGFR inhibitors. In addition, the use of agents that
benefit the increase of apoptotic potential may further increase the
sensitivity of tumor cells to targeted drugs. For example, it has
been reported that ROS-generating agents have selective killing
effects in targeted-therapy-resistant cancers [69,70]. Conversely,
agents that can help to mitigate apoptotic potential could decrease
the sensitivity of tumor cells to the EGFR inhibitors [59], which
should be avoided to use clinically. Finally, this study also suggests
that a good anti-cancer target should have a character that its
functional inhibition should benefit the release of accumulated
apoptosis potential in cancer cells, in addition to the blockade of
survival.
In summary, our systems biology modeling reveals that there
is a stronger apoptotic potential existing in the EGFR-addicted
cancers, which is largely suppressed by the negative crosstalk
between PI3K/AKT and ASK1/p38 signaling pathways.
Inhibition of survival signals and concomitant release of
accumulated apoptotic potential jointly contribute to the tumor
cell death following the inhibition of addicted oncogene in
EGFR addicted cancers. Overall, this is the first attempt to
understand ‘‘oncogene addiction’’ from the systems biology’s
viewpoint. Further insights into the mechanisms underlying the
oncogene addiction from the systems biology’s viewpoint are still
strongly required. Any advances in this field would ultimately
Figure 9. Vitamin c treatment reduces the apoptosis of HCC827 cells after gefitinib treatment. HCC827 cells were treated with vitamin c
(vc), gefitinib (gef) or their combination (gef+vc). (A) Flow cytometry detecting the apoptosis of HCC827 cells under each treatment for 24 hours. The
apoptosis rates of treatments are given as percentages. (B) Immunoblotting with indicated antibodies to show the phosphorylation of ERK, AKT and
p38 in HCC827 cells treated by indicated agents. 1 mM gefitinib, 1 mM vitamin c or their combination were used. (C) The cell viability of HCC827 cells
exposure to indicated agents measured by MTT. 1 nM gefitinib, 10 nM vitamin c or their combination were used.
doi:10.1371/journal.pone.0028930.g009
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drug development.
Materials and Methods
Model Development
The network model was developed with the aid of Matlab
(MathWorks, MA, USA, http://www.mathworks.com). The
information for all the signaling pathways and topology of the
network was collected from various published works. Molecular
interactions in the model were described by a set of coupled
ODEs, which were derived based on laws of Mass Action. For
enzymatic reactions, the reaction constant (K) and turn-over rates
(Kcats) were used instead of the Michaelis-Menten constants (Km)
that are primarily applicable to steady-state models. These ODEs
were solved using the sundials solvers in MatLab.
Sensitivity Analysis
Sensitivity analysis was performed to identify important species
that control signaling networks. Normalized, time-integrated
sensitivities of each species were calculated by varying the initial
value of them and simulating the perturbed system output (for
example, phospho-AKT, -ERK and -p38). The normalized
sensitivity S was calculated according to the following equation:
S~(dx=x)=(dy=y)
Where S corresponds to the normalized integrated sensitivity and
x is any output species and y is each species with non-zero initial
amount.
Cell Lines and Cell Culture
The human lung cancer cell lines NCI-HCC827 and NCI-
H460 were obtained from the American Type Culture Collection
(ATCC, Manassas, VA), and were cultured in RPMI 1640 (Life
Technologies, Bedford, MA) containing 10% heat-inactivated fetal
bovine serum, 100 units/ml penicillin and 100 units/ml
streptomycin in a humid chamber at 37uC under 5% CO2 in
atmosphere. Gefitinib (AstraZeneca), wortmannin (Cell Signaling)
and vitamin C (Sigma) were used as drugs treating cancer cells.
Stock solutions of all drugs were prepared in dimethyl sulfoxide
(DMSO) and stored at 220uC.
Flow cytometry assays
Flow cytometric analysis was done to identify apoptotic cells and
to measure the percentage of apoptotic cells after propidium
iodide staining in hypotonic buffer as described [69]. Briefly, cells
were suspended in 1 mL hypotonic fluorochrome solution
containing 50 mg propidium iodide/mL in 0.1% sodium citrate
plus 0.1% Triton X-100 and the cells were analyzed by flow
cytometer (ESP Elite, Beckman-Coulter, Miami, FL). Apoptotic
cells appeared in the cell cycle distribution as cells with a DNA
content of less than that of G1 cells and were estimated with
Listmode software.
Cell viability assay
NCI-HCC827 and NCI-H460 cells (4–5610
3) were seeded in
96-well plates and treated with gefitinib or vitamin c, or
combination of them. Followed by 3 day incubation after these
drug treatments, cells were then incubated with 3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) re-
agent for 4 hours, lysed with DMSO, and quantified by a plate
reader. The data were graphically displayed using GraphPad
Prism version 5.00 for Windows. Each point (mean (+/2 standard
deviation)) represents growth of treated cells compared to
untreated cells. The curves were fitted using a non-linear
regression model with a sigmoidal dose response.
Western Blot Analysis
Whole-cell lysates were extracted with cell lysis buffer for
Western blotting (Beyotime) supplemented with 1 mM PMSF
(Beyotime). Protein content was determined using BCA protein
assay kit (Beyotime). Lysates were mixed with 56sodium
dodecyl sulfate (SDS)- polyacrylamide gel electrophoresis
(PAGE) sample loading buffer (Beyotime) and denatured in a
boiling water bath for 5 minutes. Protein extracts were
separated by SDS-PAGE on 10% polyacrylamide Tris/glycine
gels and transferred onto a polyvinylidene difluoride membrane
(Millipore). Membranes were blocked in Tris-buffered saline
(TBS) containing 0.1% Tween and 10% nonfat dry milk for
1 hour. Antibodies were diluted in TBS containing 0.1% Tween
and 5% nonfat dry milk. Blots were incubated with the
corresponding primary antibody (1:1000) overnight. Then, blots
were incubated for 1 hour with the corresponding horseradish
peroxidase-linked secondary antibodies (Santa Cruz) diluted
1:5,000 in TBS containing 0.05% Tween, and 0.5% nonfat dry
milk. The primary antibodies used for the Western blot analyses
include anti-p38a MAPK, anti-phospho-p38a MAPK, anti-
ERK 1/2, anti-phospho-ERK1/2, anti-AKT, and anti-phos-
pho-AKT from Cell Signaling Technology; and anti-b actin
from Sigma. Following secondary antibody reaction, the
proteins were detected with BeyoECL reagents (Beyotime) by
exposure on a Kodak film.
Determination of Intracellular ROS Levels
To visualize intracellular ROS of cancer cells, proliferating cells
were grown on 6 well plates, washed once with warm PBS, and
incubated with 10 mM 29,79-dichlorodihydrofluorescein diacetate
(DCFH-DA, Beyotime) in warm PBS supplemented with 5.5 mM
glucose. After 10 minutes at 37uC, PBS was replaced with
complete culture medium, and cells were incubated for an
additional 20–30 minutes, washed once again with warm PBS.
Cells were incubated with 1 mM 4,6-diamidino-2-phenylindole
(DAPI) for nuclei staining (Sigma) and intracellular ROS levels
were visualized by using an inverted fluorescence microscope,
Leica DM5000B, coupled to a Leica DC500 camera. Pictures
were taken at 206magnification with the Leica IM50 software.
Statistical analysis
Data were presented as the mean6SD error of the mean.
Student’s t test was used for comparison among different groups. A
P value of less than 0.05 is considered statistically significant.
Supporting Information
Figure S1 ROS levels in H460 cells with or without
gefitinib treatment. The ROS probe signals as well as the
DAPI nuclear localization in H460 cells were presented alone or
merged (merge).
(TIF)
Table S1 Biochemical reactions involved in the computational
model together with corresponding parameters.
(DOC)
Table S2 Initial conditions of the computational model.
(DOC)
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